YU14703A - Derivati pirazola i njihova upotreba kao inhibitora protein kinaze - Google Patents
Derivati pirazola i njihova upotreba kao inhibitora protein kinazeInfo
- Publication number
- YU14703A YU14703A YU14703A YUP14703A YU14703A YU 14703 A YU14703 A YU 14703A YU 14703 A YU14703 A YU 14703A YU P14703 A YUP14703 A YU P14703A YU 14703 A YU14703 A YU 14703A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- formula
- compounds
- syndrome
- pharmaceutical compositions
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Pronalazak se odnosi na jedinjenja formule (I) gde su R1, R2, R3 i R4 kao sto je definisano i njihove farmaceutski prihvatljive soli. Jedinjenja formule (1) pokazuju ativnost u inhibiranju cdk2 i GSK-3. Farmaceutski preparati i metode sastavljeni od jedinjenja formule (1) za lecenje i prevenciju oboljenja i stanja povezanih sa abnormalnim rastom celija, kao sto je rak, i neurodegenerativna oboljenja i stanja povezana sa neurotransmisijom dopamina. Takodje su opisani farmaceutski preparati i postupci jedinjenja formule (1), za lecenje neplodnosti kod muskaraca i pokretljivosti sperme; dijabetes melitus-a, poremecaja otpornosti na glukozu, metabolickog sindroma ili sindroma X; sindroma policisticnih jajnika; adipogeneze i gojaznosti; miogeneze i neotpornosti; na primer, smanjenje fizicke izdrzljivosti pvoezane sa starenjem; akutne sarkopenie, na primer, misicne atrofije i/ili kaheksije povezane sa opekotinama; posledice lezanja u krevetu, imobilizacijom uda ili velike operacije toraksa, abdomena i/ili ortopedskog zahvata; sepse, povreda kicmenog stuba, gubitka kose, tanjenja kose i celavosti i imunodeficijencije.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22941500P | 2000-08-31 | 2000-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU14703A true YU14703A (sh) | 2006-05-25 |
Family
ID=22861151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU14703A YU14703A (sh) | 2000-08-31 | 2001-08-24 | Derivati pirazola i njihova upotreba kao inhibitora protein kinaze |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1313710A1 (sh) |
JP (1) | JP2004507526A (sh) |
KR (1) | KR20030027093A (sh) |
CN (1) | CN1518543A (sh) |
AP (1) | AP2001002266A0 (sh) |
AR (1) | AR035345A1 (sh) |
AU (1) | AU2001280009A1 (sh) |
BG (1) | BG107455A (sh) |
BR (1) | BR0113574A (sh) |
CA (1) | CA2420363A1 (sh) |
CR (1) | CR6881A (sh) |
CZ (1) | CZ2003468A3 (sh) |
DO (1) | DOP2001000243A (sh) |
DZ (1) | DZ3398A1 (sh) |
EA (1) | EA200300205A1 (sh) |
EC (1) | ECSP034480A (sh) |
EE (1) | EE200300085A (sh) |
GT (1) | GT200100179A (sh) |
HN (1) | HN2001000192A (sh) |
HR (1) | HRP20030140A2 (sh) |
HU (1) | HUP0302669A3 (sh) |
IL (1) | IL154016A0 (sh) |
IS (1) | IS6687A (sh) |
MA (1) | MA26946A1 (sh) |
MX (1) | MXPA03001785A (sh) |
NO (1) | NO20030958L (sh) |
NZ (1) | NZ523656A (sh) |
OA (1) | OA12368A (sh) |
PA (1) | PA8528101A1 (sh) |
PE (1) | PE20020470A1 (sh) |
PL (1) | PL360742A1 (sh) |
SK (1) | SK2002003A3 (sh) |
SV (1) | SV2002000618A (sh) |
TN (1) | TNSN01132A1 (sh) |
UY (1) | UY26909A1 (sh) |
WO (1) | WO2002018346A1 (sh) |
YU (1) | YU14703A (sh) |
ZA (1) | ZA200301064B (sh) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03005606A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
IL161047A0 (en) * | 2001-09-27 | 2004-08-31 | Applied Research Systems | Pyrazole derivatives for increasing endogenous testosterone levels |
US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
CA2492673A1 (en) * | 2002-07-17 | 2004-01-22 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
AU2003263518A1 (en) * | 2002-10-09 | 2004-05-04 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
AU2003301302A1 (en) * | 2002-10-15 | 2004-05-04 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
ATE410415T1 (de) * | 2003-02-27 | 2008-10-15 | Smithkline Beecham Corp | Neue verbindungen |
DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
AU2004258841B8 (en) * | 2003-06-05 | 2010-01-07 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
JP2006528661A (ja) * | 2003-07-25 | 2006-12-21 | ファイザー・インク | アミノピラゾール化合物およびchk1阻害剤としての使用 |
US7671072B2 (en) * | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
JP2007533717A (ja) * | 2004-04-21 | 2007-11-22 | アストラゼネカ アクチボラグ | 化合物 |
JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US7521560B2 (en) | 2004-06-29 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses |
US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
BRPI0517737A (pt) | 2004-11-17 | 2008-10-21 | Miikana Therapeutics Inc | inibidores de quinase |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
PL1846394T3 (pl) | 2005-02-04 | 2012-04-30 | Astrazeneca Ab | Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy |
JPWO2006085685A1 (ja) * | 2005-02-09 | 2008-06-26 | 武田薬品工業株式会社 | ピラゾール化合物 |
SI1853588T1 (sl) | 2005-02-16 | 2008-10-31 | Astrazeneca Ab | Kemične spojine |
EP1899323A2 (en) | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
EP1741708A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
KR101487027B1 (ko) | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
SG166827A1 (en) | 2005-11-03 | 2010-12-29 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
RU2009118359A (ru) | 2006-10-18 | 2010-11-20 | Перинесс Лтд. (Il) | Способ и фармацевтическая композиция для диагностики и лечения недостаточности репродуктивной функции у мужчин |
EP2091943B1 (en) * | 2006-10-21 | 2013-11-20 | AbbVie Deutschland GmbH & Co KG | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
NZ583538A (en) | 2007-09-21 | 2012-06-29 | Array Biopharma Inc | Pyridin-2-yl-amino-1,2,4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
WO2009130900A1 (ja) * | 2008-04-24 | 2009-10-29 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AR078033A1 (es) | 2009-04-03 | 2011-10-12 | Plexxikon Inc | Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de |
WO2011041634A1 (en) * | 2009-10-02 | 2011-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP5998142B2 (ja) | 2010-09-27 | 2016-09-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 複素環化合物およびグリコーゲンシンターゼキナーゼ−3阻害薬としてのその使用 |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
PE20141360A1 (es) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
CN105612157B (zh) * | 2013-08-16 | 2019-08-09 | 默克专利股份公司 | 3-取代的环戊基胺衍生物 |
CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
JP2022516057A (ja) | 2018-12-31 | 2022-02-24 | バイオメア フュージョン,エルエルシー | メニン-mll相互作用の不可逆的阻害剤 |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
JP7094456B2 (ja) * | 2019-01-31 | 2022-07-01 | ファイザー・インク | Cdk2阻害剤 |
WO2022135442A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Cdk2抑制剂及其制备方法 |
CA3223223A1 (en) | 2021-06-28 | 2023-01-05 | Blueprint Medicines Corporation | Cdk2 inhibitors |
TW202317564A (zh) * | 2021-07-01 | 2023-05-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2抑制劑及其製備方法和用途 |
TW202325280A (zh) * | 2021-11-09 | 2023-07-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種胺基吡唑衍生物及其製備方法和用途 |
WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ505844A (en) * | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
KR100579792B1 (ko) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | 신규 2,5-피리딘디카복실산 유도체 |
GB9811427D0 (en) * | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
EP1199306B1 (en) * | 1999-07-26 | 2005-12-07 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
ATE305782T1 (de) * | 1999-08-12 | 2005-10-15 | Pharmacia Italia Spa | 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel |
US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
WO2001040215A1 (en) * | 1999-11-30 | 2001-06-07 | Pfizer Products Inc. | 2,4-diaminopyrimidine compounds usful as immunosuppressants |
CA2398446A1 (en) * | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
-
2001
- 2001-08-24 PL PL36074201A patent/PL360742A1/xx not_active Application Discontinuation
- 2001-08-24 AU AU2001280009A patent/AU2001280009A1/en not_active Abandoned
- 2001-08-24 EA EA200300205A patent/EA200300205A1/ru unknown
- 2001-08-24 CA CA002420363A patent/CA2420363A1/en not_active Abandoned
- 2001-08-24 WO PCT/IB2001/001540 patent/WO2002018346A1/en not_active Application Discontinuation
- 2001-08-24 DZ DZ013398A patent/DZ3398A1/xx active
- 2001-08-24 EP EP01958287A patent/EP1313710A1/en not_active Withdrawn
- 2001-08-24 CN CNA018147615A patent/CN1518543A/zh active Pending
- 2001-08-24 JP JP2002523464A patent/JP2004507526A/ja active Pending
- 2001-08-24 BR BR0113574-0A patent/BR0113574A/pt not_active IP Right Cessation
- 2001-08-24 HU HU0302669A patent/HUP0302669A3/hu unknown
- 2001-08-24 NZ NZ523656A patent/NZ523656A/en unknown
- 2001-08-24 AP APAP/P/2001/002266A patent/AP2001002266A0/en unknown
- 2001-08-24 EE EEP200300085A patent/EE200300085A/xx unknown
- 2001-08-24 KR KR10-2003-7002894A patent/KR20030027093A/ko not_active Application Discontinuation
- 2001-08-24 IL IL15401601A patent/IL154016A0/xx unknown
- 2001-08-24 OA OA1200300050A patent/OA12368A/en unknown
- 2001-08-24 CZ CZ2003468A patent/CZ2003468A3/cs unknown
- 2001-08-24 YU YU14703A patent/YU14703A/sh unknown
- 2001-08-24 SK SK200-2003A patent/SK2002003A3/sk not_active Application Discontinuation
- 2001-08-24 MX MXPA03001785A patent/MXPA03001785A/es not_active Application Discontinuation
- 2001-08-27 UY UY26909A patent/UY26909A1/es not_active Application Discontinuation
- 2001-08-28 HN HN2001000192A patent/HN2001000192A/es unknown
- 2001-08-29 DO DO2001000243A patent/DOP2001000243A/es unknown
- 2001-08-29 PE PE2001000872A patent/PE20020470A1/es not_active Application Discontinuation
- 2001-08-29 AR ARP010104115A patent/AR035345A1/es unknown
- 2001-08-30 SV SV2001000618A patent/SV2002000618A/es unknown
- 2001-08-30 TN TNTNSN01132A patent/TNSN01132A1/fr unknown
- 2001-08-30 GT GT200100179A patent/GT200100179A/es unknown
- 2001-08-31 PA PA20018528101A patent/PA8528101A1/es unknown
-
2003
- 2003-01-13 BG BG107455A patent/BG107455A/xx unknown
- 2003-01-15 CR CR6881A patent/CR6881A/es not_active Application Discontinuation
- 2003-01-16 IS IS6687A patent/IS6687A/is unknown
- 2003-02-07 ZA ZA200301064A patent/ZA200301064B/en unknown
- 2003-02-17 EC EC2003004480A patent/ECSP034480A/es unknown
- 2003-02-21 MA MA27050A patent/MA26946A1/fr unknown
- 2003-02-26 HR HR20030140A patent/HRP20030140A2/hr not_active Application Discontinuation
- 2003-02-28 NO NO20030958A patent/NO20030958L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU14703A (sh) | Derivati pirazola i njihova upotreba kao inhibitora protein kinaze | |
AP2001002232A0 (en) | Imidazole derivatives | |
BR0201691A (pt) | Derivados de tiazol | |
BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
EE200300083A (et) | Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid | |
JO2353B1 (en) | New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use | |
NO20064412L (no) | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav | |
MY137039A (en) | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | |
WO2004005281A8 (en) | Inhibitors of tyrosine kinases | |
BR0208811A (pt) | Derivados de pirazol para tratamento de hiv | |
NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
AU2267395A (en) | Benzofuran derivatives useful as inhibitors of bone resorption | |
IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
TW200615266A (en) | Organic compounds | |
WO2003080617A8 (en) | Pyrazolopyrimidine derivatives | |
WO2004037166A3 (en) | Therapeutic guanidines | |
ATE440835T1 (de) | Heterozyklische harnstoff-derivate für die behandlung von schmerzen. | |
TW200510370A (en) | Urea derivatives | |
DK1218401T3 (da) | 4-Benzylaminoquinolin-konjugat med galdesyre og deres heteroanaloger, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
IL160604A0 (en) | C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | |
BR0008559A (pt) | Aminas tiazol-2-ilideno policìclicas, processos paraa sua preparação e seu emprego comomedicamento | |
NO20072090L (no) | Forbindelser, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav II | |
BR0206896A (pt) | Derivados de beta-carbolina úteis como inibidores de fosfodiesterase |